The 2001 Canadian recommendations for the management of hypertension: Part one - Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification

Canadian Journal of Cardiology

Volumn 18, Issue 6, 2002, Pages 604-624

  Zarnke, Kelly B ^a   McAlister, Finlay A ^a   Campbell, Norman R C ^a   Levine, Mitchell ^a   Schiffrin, Ernesto L ^a   Grover, Steven ^a   McKay, Donald W ^a   Myers, Martin G ^a   Wilson, Thomas W ^a   Rabkin, Simon W ^a   Feldman, Ross D ^a   Burgess, Ellen ^a   Bolli, Peter ^a   Honos, George ^a   Lebel, Marcel ^a   Mann, Karen ^a   Abbott, Carl ^a   Tobe, Sheldon ^a   Petrella, Robert ^a   Touyz, Rhian M ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Blood pressure; Diagnosis; Hypertension; Risk factors

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CREATININE; CYCLOPHOSPHAMIDE; DACARBAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FLUDRICORTISONE; METHYLDOPA; METIROSINE; PHENOXYBENZAMINE; PHENTOLAMINE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PROPRANOLOL; SODIUM; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TYROSINE 3 MONOOXYGENASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE DURATION; DOSE RESPONSE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LABORATORY TEST; LAPAROSCOPIC SURGERY; LIFESTYLE; META ANALYSIS; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CANADA; CARDIOVASCULAR DISEASES; DIET; EXERCISE; FEMALE; HUMANS; HYPERTENSION; LIFE STYLE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK ASSESSMENT;

EID: 0036056573     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. A novel process for updating recommendations for managing hypertension: Rationale and methods
2. 1999 Canadian recommendations for the management of hypertension
3. The 2000 Canadian recommendations for the management of hypertension: Part one - Therapy
4. The 2000 Canadian recommendations for the management of hypertension: Part two - Diagnosis and assessment of persons with high blood pressure
5. Arm position is important for blood pressure measurement
6. The effect of crossing legs on blood pressure: A randomized single-blind cross-over study
7. Measurement of blood pressure: An evidence based review
8. Consequences of banning mercury and the cuff controversy
9. Replacing the mercury sphygmomanometer. Requires clinicians to demand better automated devices
10. A comparison of the British Hypertension Society and Association for the Advancement of Medical Instrumentation protocols for validating blood pressure measuring devices: Can the two be reconciled?
11. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices
12. Blood pressure measuring devices: Recommendations of the European Society of Hypertension
13. Predictive values of routine blood pressure measurements in screening for hypertension
14. Difficulties in diagnosing hypertension: Implications and alternatives
15. How many measurements are necessary in diagnosing mild to moderate hypertension?
16. Prediction of coronary heart disease using risk factor categories
17. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics
18. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: Evidence based review
19. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
20. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group
21. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
22. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
23. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors
24. Updated New Zealand cardiovascular disease risk-benefit prediction guide
25. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
26. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association
27. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?
28. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS)
29. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: Randomised controlled trial
30. The Prospective Cardiovascular Muenster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease
31. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs
32. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association
33. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: A randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group
34. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group
35. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group
36. Long-term outcome with surgical treatment of renovascular hypertension
37. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia
38. Percutaneous transluminal angioplasty: The treatment of choice for renovascular hypertension due to fibromuscular dysplasia
39. A clinical prediction rule for renal artery stenosis
40. Possible familial origin of multifocal renal artery fibromuscular dysplasia
41. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril
42. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis
43. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical revascularisation
44. Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization. The Yale Vascular Center experience
45. Simplified captopril renography in diagnosis and treatment of renal artery stenosis
46. Captopril renography in the diagnosis of renal artery stenosis: Accuracy and limitations
47. Captopril radionuclide test in renovascular hypertension: A European multicentre study. European Multicentre Study Group
48. The place of renal scintigraphy in the diagnosis of renal artery stenosis. Fifteen years of clinical experience
49. Prospective study of simultaneous orthoiodohippurate and diethylenetriaminepentaacetic acid captopril renography. The Einstein/Cornell Collaborative Hypertension Group
50. Imaging of renovascular hypertension: Respective values of renal scintigraphy, renal Doppler US, and MR angiography
51. Diagnosis of renal artery stenosis and renovascular hypertension
52. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis
53. Renovascular hypertension with low-to-normal plasma renin: Clinical and angiographic features
54. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: A meta-analysis
55. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests
56. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore
57. Potentially high prevalence of primary aldosteronism in a primary-care population
58. High prevalence of primary aldosteronism in the Tayside hypertension clinic population
59. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology
60. Primary hyperaldosteronism: A missed diagnosis in 'essential hypertensives'?
61. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients
62. Primary aldosteronism
63. Potassium and aldosterone secretion in glucocorticoid-remediable aldosteronism
64. Primary aldosteronism: Rare bird or common cause of secondary hypertension?
65. High incidence of primary aldosteronism in 1999 patients referred with hypertension
66. Use of the saline infusion test to diagnose the cause of primary aldosteronism
67. Single dose captopril as a diagnostic test for primary aldosteronism
68. Captopril suppression versus salt loading in confirming primary aldosteronism
69. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma
70. Diagnosis and localization of aldosterone-producing adenomas by adrenal-vein catheterization
71. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: Reliability of CT
72. Efficacy of iodine-131 6beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism
73. Primary hyperaldosteronism and adrenal incidentaloma: An argument for physiologic testing before adrenalectomy
74. Primary aldosteronism. Results of surgical treatment
75. Adrenal surgery in the elderly: Too risky?
76. Adrenalectomy in primary aldosteronism: A long-term follow-up study in 52 patients
77. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery
78. A review of the medical treatment of primary aldosteronism
79. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study
80. Recent progress in the diagnosis, prognostic evaluation and treatment of pheochromocytomas
81. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma
82. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis
83. Pheochromocytoma in Italy: A multicentric retrospective study
84. Changes in clinical features and long-term prognosis in patients with pheochromocytoma
85. Pheochromocytoma
86. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma
87. Plasma metanephrines in the diagnosis of pheochromocytoma
88. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma
89. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2
90. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls
91. Clonidine-suppression test: A useful aid in the diagnosis of pheochromocytoma
92. Glucagon and clonidine testing in the diagnosis of pheochromocytoma
93. Basis of false-positive glucagon tests for pheochromocytoma
94. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: A review of 282 cases. French Association of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE)
95. The predictive value of diagnostic tests for pheochromocytoma
96. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison
97. Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma
98. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas
99. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma
100. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients
101. Pheochromocytoma and sudden death
102. Phaeochromocytoma and acute cardiovascular death (with special reference to myocardial infarction)
103. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series
104. Death from phaeochromocytoma: Lessons from a post-mortem survey
105. Treatment of pheochromocytomas with retroperitoneal laparoscopy
106. Surgical treatment of pheochromocytomas: Laparoscopic or conventional?
107. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma
108. Pheochromocytoma and prazosin
109. Prazosin in the preoperative management of patients with phaeochromocytoma
110. Prazosin and propranolol in preoperative management of pheochromocytoma
111. Doxazosin: A newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma
112. Metyrosine and pheochromocytoma
113. Surgical management of pheochromocytoma with the use of metyrosine
114. Preoperative treatment and survival of patients with pheochromocytomas
115. Preoperative acute volume loading in patients with pheochromocytoma
116. Postoperative management of patients with pheochromocytoma
117. Pheochromocytoma and pregnancy: The epitome of high risk
118. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine
119. Treatment of malignant pheochromocytoma with combination chemotherapy
120. Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor
121. Comparison of the oscillometric blood pressure monitor (BPM-100Beta) with the ausculatory mercury sphygmomanometer
122. Self-recording of blood pressure in the management of hypertension
123. Improvement of medication compliance in uncontrolled hypertension
124. Effects of intensified antihypertensive treatment in diabetic nephropathy: Mortality and morbidity results of a prospective controlled 10-year study
125. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy
126. Proposal of reference values for home blood pressure measurement: Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan
127. Reference values for self-recorded blood pressure: A meta-analysis of summary data
128. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan
129. Predictive value of home blood pressure measurement in relation to stroke morbidity: A population-based pilot study in Ohasama, Japan
130. White coat effect detected using self-monitoring of blood pressure at home: Comparison with ambulatory blood pressure
131. Diagnosis of hypertension using home or ambulatory blood pressure monitoring: Comparison with the conventional strategy based on repeated clinic blood pressure measurements
132. Home self-measurement of blood pressure and relationship with diagnosis of hypertension and target organ damage: Comparative study with ambulatory monitoring
133. Assessment of blood pressure in patients with Type 2 diabetes: Comparison between home blood pressure monitoring, clinic blood pressure measurement and 24-h ambulatory blood pressure monitoring
134. Factors affecting the difference between screening and home blood pressure measurements: The Ohasama Study
135. Self-measurement of blood pressure: Assessment of equipment. Canadian Coalition for High Blood Pressure Prevention and Control
136. Guidelines for the use of self-blood pressure monitoring: A summary report of the First International Consensus Conference. Groupe Evaluation & Measure of the French Society of Hypertension
137. Management of hypertension in the elderly using home blood pressures
138. The feasibility of at-home self-monitoring blood pressure in elderly hypertensive patients
139. Blood pressure self-measurement in the elderly: Differences between automatic and semi-automatic systems
140. Self-measurement of blood pressure: Recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control
141. Self-measurement of blood pressure: Issues related to the training of patients. Canadian Coalition for High Blood Pressure Prevention and Control
142. Self-measurement of blood pressure at home: The potential for reporting bias
143. Reliability of reporting self-measured blood pressure values by hypertensive patients
144. Reliability of patients measuring blood pressure at home: Prospective observational study
145. Reliability of self-reported blood pressure measurements
146. Home blood pressure measurement: Reliability of patients' reports, acceptability and comparison with office and ambulatory blood pressure
147. Home blood pressure normalcy: The Didima study
148. Home blood pressure: Accuracy is independent of monitoring schedules
149. Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the British Hypertension Society
150. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: The Ohasama Study
151. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension
152. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators
153. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure
154. Physical activity level is an independent predictor of the diurnal variation in blood pressure
155. Ambulatory physical activity as a determinant of diurnal blood pressure variation
156. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension
157. Prognostic value of 24-hour blood pressure variability
158. Prognostic significance of blood pressure variability in essential hypertension
159. Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study
160. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
161. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function
162. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement
163. Effect of regression to the mean in serial echocardiographic measurements of left ventricular mass. Quantification and clinical implications
164. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group
165. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: From the Investigators of Consensus on Diastolic Dysfunction by Echocardiography
166. Guidelines from the Canadian Cardiovascular Society and the Canadian Hypertension Society on the echocardiographic determination of left ventricular mass. Task Force of the Echocardiography Section
167. Lifestyle changes to prevent and control hypertension: Do they work? A summary of the Canadian consensus conference
168. Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada
169. Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada
170. Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada
171. Aerobic exercise and resting blood pressure in older adults: A meta-analytic review of randomized controlled trials
172. Aerobic exercise and resting blood pressure among women: A meta-analysis
173. Effects of alcohol restriction on 24-hour ambulatory blood pressure in Japanese men with hypertension
174. Placebo-controlled biofeedback blood pressure effect in hypertensive humans
175. The effect of home training with direct blood pressure biofeedback of hypertensives: A placebo-controlled study
176. Comparison of single versus multiple lifestyle interventions: Are the antihypertensive effects of exercise training and diet-induced weight loss additive?
177. The influence of dietary and nondietary calcium supplementation on blood pressure: An updated metaanalysis of randomized controlled trials
178. Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension
179. Effects of magnesium supplementation in hypertensive patients: Assessment by office, home, and ambulatory blood pressures
180. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group
181. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group
182. The 2000 Canadian Hypertension Recommendations: A summary. The Canadian Hypertension Recommendations Working Group
183. Résumé des recommendations Canadiennes de l'an 2000 sur l'hypertension. Le groupe de travail sur les recommendations Canadiennes sur l'hypertension